Genelux Files Routine 8-K on Operations & Other Events
Ticker: GNLX · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1231457
| Field | Detail |
|---|---|
| Company | Genelux Corp (GNLX) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $23.2 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, compliance
TL;DR
**Genelux filed a routine 8-K, no new material news.**
AI Summary
Genelux Corporation filed an 8-K on February 2, 2024, indicating a routine filing for 'Results of Operations and Financial Condition' and 'Other Events'. This filing primarily serves to update the public record with basic company information, such as its address at 2625 Townsgate Road, Suite 230, Westlake Village, California, and its Nasdaq trading symbol GNLX. For investors, this filing is a standard procedural update and does not contain new material financial or operational news, meaning it's unlikely to cause immediate stock price movement.
Why It Matters
This filing is a standard procedural update, confirming basic company information and compliance with SEC reporting requirements, but it does not disclose new material financial or operational news.
Risk Assessment
Risk Level: low — This 8-K is a standard informational filing and does not contain any new disclosures that would introduce or mitigate significant risks.
Analyst Insight
Investors should note this is a routine compliance filing and does not contain new material information that would warrant immediate trading action. It's a good reminder to check for more substantive filings like 10-K or 10-Q for financial performance updates.
Key Numbers
- $0.001 — par value per share (the par value of Genelux's common stock)
Key Players & Entities
- Genelux Corporation (company) — the registrant filing the 8-K
- Nasdaq Stock Market LLC (company) — the exchange where Genelux's common stock is registered
- GNLX (company) — the trading symbol for Genelux Corporation
- February 2, 2024 (date) — the date of the earliest event reported and filing date
- 2625 Townsgate Road, Suite 230 (other) — Genelux Corporation's business address
- Westlake Village, California (other) — Genelux Corporation's business city and state
- 001-41599 (other) — Genelux Corporation's Commission File Number
- Delaware (other) — Genelux Corporation's state of incorporation
FAQ
What is the purpose of this 8-K filing by Genelux Corporation?
This 8-K filing by Genelux Corporation is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Results of Operations and Financial Condition' and 'Other Events' as of February 2, 2024. It primarily serves to update the public record with routine company information.
What is Genelux Corporation's trading symbol and where is its stock registered?
Genelux Corporation's trading symbol is GNLX, and its common stock, with a par value of $0.001 per share, is registered on The Nasdaq Stock Market LLC.
What is the business address and phone number of Genelux Corporation as stated in the filing?
The business address of Genelux Corporation is 2625 Townsgate Road, Suite 230, Westlake Village, California, 91361. The registrant's telephone number is (805) 267-9889.
What is the earliest event reported date for this 8-K filing?
The date of the earliest event reported for this 8-K filing is February 2, 2024.
Is Genelux Corporation an emerging growth company according to this filing?
The filing includes a checkbox section to indicate if the registrant is an emerging growth company, but the box is not checked, implying the filing does not explicitly state whether Genelux Corporation is an emerging growth company.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-02-02 16:39:06
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar
- $23.2 million — of December 31, 2023 were approximately $23.2 million. The Company has not yet completed it
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-004778.txt ( ) — 210KB
- gnlx-20240202.xsd (EX-101.SCH) — 3KB
- gnlx-20240202_lab.xml (EX-101.LAB) — 33KB
- gnlx-20240202_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: February 2, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer